An Optimized Mouse Thigh Infection Model for Enterococci and Its Impact on Antimicrobial Pharmacodynamics

ABSTRACT Negligible in vivo growth of enterococci and high-level dispersion of data have led to inaccurate estimations of antibiotic pharmacodynamics (PD). Here we improved an in vivo model apt for PD studies by optimizing the in vitro culture conditions for enterococci. The PD of vancomycin (VAN), ampicillin-sulbactam (SAM), and piperacillin-tazobactam (TZP) against enterococci were determined in vivo, comparing the following different conditions of inoculum preparation: aerobiosis, aerobiosis plus mucin, and anaerobiosis plus mucin. Drug exposure was expressed as the ratio of the area under the concentration-time curve for the free, unbound fraction of the drug to the MIC (fAUC/MIC) (VAN) or the time in a 24-h period that the drug concentration for the free, unbound fraction exceeded the MIC under steady-state pharmacokinetic conditions (fT>MIC) (SAM and TZP) and linked to the change in log10 CFU/thigh. Only anaerobiosis plus mucin enhanced the in vivo growth, yielding significant PD parameters with all antibiotics. In conclusion, robust in vivo growth of enterococci was crucial for better determining the PD of tested antibacterial agents, and this was achieved by optimizing the procedure for preparing the inoculum.

[1]  Andres F Zuluaga,et al.  About the validation of animal models to study the pharmacodynamics of generic antimicrobials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Melissa J. Martin,et al.  Structure, Function, and Biology of the Enterococcus faecalis Cytolysin , 2013, Toxins.

[3]  Alan Schumitzky,et al.  Accurate Detection of Outliers and Subpopulations With Pmetrics, a Nonparametric and Parametric Pharmacometric Modeling and Simulation Package for R , 2012, Therapeutic drug monitoring.

[4]  Christina A. Sutherland,et al.  In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms , 2011, Antimicrobial Agents and Chemotherapy.

[5]  Clsi.  Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[6]  Andres F Zuluaga,et al.  Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator , 2010, Antimicrobial Agents and Chemotherapy.

[7]  Peter Sandøe,et al.  Validating Animal Models for Preclinical Research: A Scientific and Ethical Discussion , 2010, Alternatives to laboratory animals : ATLA.

[8]  C. A. Rodriguez,et al.  Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model , 2010, PloS one.

[9]  Brian Van Scoy,et al.  The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression , 2010, Antimicrobial Agents and Chemotherapy.

[10]  Y. Ueda,et al.  Pharmacodynamics of SMP-601 (PTZ601) against Vancomycin-Resistant Enterococcus faecium and Methicillin-Resistant Staphylococcus aureus in Neutropenic Murine Thigh Infection Models , 2009, Antimicrobial Agents and Chemotherapy.

[11]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[12]  M. Dudley,et al.  Pharmacodynamics of RWJ-54428 against Staphylococcus aureus, Streptococcus pneumoniae, and Enterococcus faecalis in a Neutropenic Mouse Thigh Infection Model , 2008, Antimicrobial Agents and Chemotherapy.

[13]  C. Arias,et al.  Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. , 2007, The Journal of antimicrobial chemotherapy.

[14]  P. Moreillon,et al.  Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. , 2006, The Journal of antimicrobial chemotherapy.

[15]  C. Donskey,et al.  Vancomycin-resistant Enterococci may obtain nutritional support by scavenging carbohydrate fragments generated during mucin degradation by the anaerobic microbiota of the colon. , 2006, Microbial drug resistance.

[16]  Andres F Zuluaga,et al.  Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases , 2006, BMC infectious diseases.

[17]  W. Craig,et al.  In Vivo Pharmacodynamic Activity of Daptomycin , 2004, Antimicrobial Agents and Chemotherapy.

[18]  D. Nicolau,et al.  Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. , 2003, The Journal of antimicrobial chemotherapy.

[19]  W. Craig.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.

[20]  J. Cove,et al.  Cytolysin gene expression in Enterococcus faecalis is regulated in response to aerobiosis conditions , 2003, Molecular Genetics and Genomics.

[21]  D. Le Guludec,et al.  Activity and Diffusion of Tigecycline (GAR-936) in Experimental Enterococcal Endocarditis , 2003, Antimicrobial Agents and Chemotherapy.

[22]  G. Borsani,et al.  Recent Development in Mammalian Sialidase Molecular Biology , 2002, Neurochemical Research.

[23]  M. Rybak,et al.  Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. , 2000, The Journal of antimicrobial chemotherapy.

[24]  M. Gilmore,et al.  Identification of Aerobically and Anaerobically Induced Genes in Enterococcus faecalis by Random Arbitrarily Primed PCR , 1999, Applied and Environmental Microbiology.

[25]  Jerome J. Schentag,et al.  The Importance of Pharmacokinetic/Pharmacodynamic Surrogate Markers to Outcome , 1995, Clinical pharmacokinetics.

[26]  R. van Furth,et al.  Comparison of the antibacterial efficacies of ampicillin and ciprofloxacin against experimental infections with Listeria monocytogenes in hydrocortisone-treated mice , 1992, Antimicrobial Agents and Chemotherapy.

[27]  A. Corfield,et al.  Mucin degradation in the human colon: production of sialidase, sialate O-acetylesterase, N-acetylneuraminate lyase, arylesterase, and glycosulfatase activities by strains of fecal bacteria , 1992, Infection and immunity.

[28]  J. Duval,et al.  Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium , 1991, Antimicrobial Agents and Chemotherapy.

[29]  F. Rombouts,et al.  Modeling of the Bacterial Growth Curve , 1990, Applied and environmental microbiology.

[30]  L. Reimer,et al.  Antibiotics in laboratory medicine , 1987 .

[31]  M. Sande,et al.  Evaluation of antimicrobial agents in the rabbit model of endocarditis. , 1981, Reviews of infectious diseases.

[32]  L. Olitzki.  MUCIN AS A RESISTANCE-LOWERING SUBSTANCE , 1948, Bacteriological reviews.

[33]  Roland Schauer,et al.  Sialidases in vertebrates: a family of enzymes tailored for several cell functions. , 2010, Advances in carbohydrate chemistry and biochemistry.

[34]  Clinical,et al.  Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .

[35]  M. Gilmore,et al.  The enterococci : pathogenesis, molecular biology, and antibiotic resistance , 2002 .

[36]  M. Huycke.  Physiology of Enterococci , 2002 .

[37]  R. Sidwell,et al.  Handbook of Animal Models of Infection , 1999 .

[38]  S. Gudmundsson,et al.  Murine Thigh Infection Model , 1999 .

[39]  W. Craig.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  Stanton A. Glantz,et al.  Primer of biostatistics : statistical software program version 6.0 , 1981 .